
Marc van de Vijver

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2579229/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Journal of Clinical Oncology, 2007, 26, 118-145.	0.8	3,139
2	The landscape of cancer genes and mutational processes in breast cancer. Nature, 2012, 486, 400-404.	13.7	1,535
3	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nature Genetics, 2011, 43, 621-629.	9.4	1,080
4	HER2 testing in gastric cancer: a practical approach. Modern Pathology, 2012, 25, 637-650.	2.9	478
5	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	6.0	348
6	Lung metastasis genes couple breast tumor size and metastatic spread. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6740-6745.	3.3	331
7	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Modern Pathology, 2014, 27, 4-18.	2.9	236
8	A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients. Cancer Research, 2005, 65, 4059-4066.	0.4	233
9	Current Perspectives on HER2 Testing: A Review of National Testing Guidelines. Modern Pathology, 2003, 16, 173-182.	2.9	229
10	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, 2017, 543, 714-718.	13.7	229
11	Determination of Stromal Signatures in Breast Carcinoma. PLoS Biology, 2005, 3, e187.	2.6	180
12	Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Research and Treatment, 2010, 119, 119-126.	1.1	142
13	Emerging Technologies for Assessing HER2 Amplification. American Journal of Clinical Pathology, 2009, 132, 539-548.	0.4	135
14	A Conditional Mouse Model for Malignant Mesothelioma. Cancer Cell, 2008, 13, 261-271.	7.7	126
15	Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy, 2014, 46, 219-224.	1.0	106
16	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 631-638.	0.4	102
17	Preoperative chemotherapy is safe in early breast cancer, even after 10Âyears of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Research and Treatment, 2009, 115, 101-113.	1.1	93
18	Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Research, 2007, 9, R68.	2.2	56

Marc van de Vijver

#	Article	IF	CITATIONS
19	Geneâ€Expression Profiling and the Future of Adjuvant Therapy. Oncologist, 2005, 10, 30-34.	1.9	55
20	Radiation-Associated Breast Tumors Display a Distinct Gene Expression Profile. International Journal of Radiation Oncology Biology Physics, 2010, 76, 540-547.	0.4	55
21	HER-2 amplification is highly homogenous in gastric cancer. Human Pathology, 2010, 41, 304-305.	1.1	38
22	Emerging Technologies for HER2 Testing. Oncology, 2002, 63, 33-38.	0.9	34
23	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 958-967.	0.4	34
24	Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 533-543.	1.4	32
25	Improving patient care through molecular diagnostics. Seminars in Oncology, 2004, 31, 14-20.	0.8	27
26	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. Cancer Research, 2019, 79, 4315-4323.	0.4	9
27	Estrogen Receptor Phenotypes Defined by Gene Expression Profiling. Cancer Treatment and Research, 2009, 147, 1-18.	0.2	1
28	Current and future pathological examination in breast cancer. European Journal of Cancer, Supplement, 2005, 3, 121-130.	2.2	0
29	Clinical Genomics in Oncology. , 2008, , 209-229.		0